| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $3.7M | -52.7% |
| Cost of Revenue | $2.5M | -29.7% |
| Gross Profit | $1.2M | -71.5% |
| R&D Expense | $2.6M | +10.7% |
| SG&A Expense | $2.9M | -8.5% |
| Operating Income | -$7.2M | -91.2% |
| Net Income | -$8.3M | -88.9% |
| EPS (Basic) | -$5.68 | -568.2% |
| EPS (Diluted) | -$5.68 | -568.2% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $4.1M | +106.3% |
| Accounts Receivable | $1.1M | -34.5% |
| Inventory | $2.5M | +1.0% |
| Current Assets | $8.6M | +24.5% |
| Total Assets | $9.5M | +15.9% |
| Current Liabilities | $3.5M | -23.8% |
| Long-term Debt | $150K | +0.0% |
| Total Liabilities |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$7.7M | -17.4% |
| Capital Expenditures | $9K | +800.0% |
| Investing Cash Flow | -$8K | -104.1% |
| Financing Cash Flow | $9.8M | +216.7% |
| Free Cash Flow | -$7.7M | -17.6% |
| $4.7M |
| -9.7% |
| Stockholders' Equity | $4.8M | +74.0% |